胰腺胶样癌与胰腺导管腺癌患者的生存和预后因素比较。
Survival and Prognostic Factors in Patients With Pancreatic Colloid Carcinoma Compared With Pancreatic Ductal Adenocarcinoma.
机构信息
From the Department of Hematology and Oncology.
Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham, Heerskink School of Medicine, Birmingham, AL.
出版信息
Pancreas. 2023 Jan 1;52(1):e75-e84. doi: 10.1097/MPA.0000000000002227.
OBJECTIVES
Colloid carcinoma (CC) is a rare subtype of pancreatic carcinoma. The aims of the study are to characterize the clinicopathological features and to evaluate the overall survival (OS) of patients with CC.
METHODS
Patients diagnosed with pancreatic CC and pancreatic ductal adenocarcinoma (PDAC) between 2004 and 2016 were identified from the National Cancer Database using International Classification of Disease-O-3 morphology (8480/3 and 8140/3) and topography (C25) codes. Kaplan-Meier analysis and Cox proportional hazards models were used to analyze OS.
RESULTS
Fifty-six thousand eight hundred forty-six patients were identified. A total of 2430 patients (4.3%) were diagnosed with pancreatic CC. Males constituted 52.8% of CC and 52.2% of PDAC. Colloid carcinoma presented with pathological stage I disease more often (16.7% vs 5.9%) and stage IV disease less often (42.1% vs 52.4%) than PDAC (P < 0.001). Stage I CC received chemotherapy (36.0% vs 59.4%) and neoadjuvant chemotherapy (4.4% vs 14.2%) less often compared with PDAC (P < 0.001). Statistically significant improved OS was seen among stage I, II, and IV CC compared with PDAC.
CONCLUSIONS
Pancreatic CC presented as stage I disease more often compared with PDAC. Neoadjuvant chemotherapy was administered more often in stage I PDAC compared with CC. Colloid carcinoma had improved OS compared with PDAC among all stages except stage III.
目的
胶样癌（CC）是一种罕见的胰腺癌亚型。本研究旨在描述其临床病理特征，并评估 CC 患者的总生存（OS）。
方法
本研究通过国际疾病分类第 0-3 版形态学（8480/3 和 8140/3）和解剖学（C25）编码，从国家癌症数据库中确定了 2004 年至 2016 年间诊断为胰腺 CC 和胰腺导管腺癌（PDAC）的患者。采用 Kaplan-Meier 分析和 Cox 比例风险模型分析 OS。
结果
共纳入 56846 例患者，其中 2430 例（4.3%）诊断为胰腺 CC。男性占 CC 的 52.8%和 PDAC 的 52.2%。CC 更常表现为病理 I 期疾病（16.7% vs. 5.9%），而较少表现为 IV 期疾病（42.1% vs. 52.4%）（P < 0.001）。与 PDAC 相比，I 期 CC 接受化疗（36.0% vs. 59.4%）和新辅助化疗（4.4% vs. 14.2%）的比例较低（P < 0.001）。与 PDAC 相比，I、II 和 IV 期 CC 的 OS 显著改善。
结论
与 PDAC 相比，胰腺 CC 更常表现为 I 期疾病。与 CC 相比，I 期 PDAC 更常接受新辅助化疗。除 III 期外，CC 的 OS 与 PDAC 相比均有改善。
Zotero 插件